Enzo Biochem, Inc.

NYSE:ENZ Stock Report

Market Cap: US$39.8m

Enzo Biochem Dividends and Buybacks

Dividend criteria checks 2/6

Enzo Biochem is a dividend paying company with a current yield of 52.45%.

Key information

52.4%

Dividend yield

0.4%

Buyback Yield

Total Shareholder Yield52.9%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareUS$0.400
Payout ratio-71%

Recent dividend and buyback updates

Recent updates

Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk

Dec 18
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk

Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?

Nov 19
Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?

Enzo Biochem: Is This Time Finally Different?

Jul 17

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Oct 26

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

May 18
Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Jan 03
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Dec 12

Enzo Biochem appoints Patricia Eckert as interim CFO

Oct 20

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Oct 14

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Oct 04
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Jun 27

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

May 03
Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Dec 17
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Aug 24
Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Mar 01
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Feb 03
Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08
If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13
Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Too early to tell whether ENZ's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if ENZ's dividend payments are increasing as they only just started paying a dividend.

Dividend Yield vs Market

Enzo Biochem Dividend Yield vs Market
How does ENZ dividend yield compare to the market?
SegmentDividend Yield
Company (ENZ)52.4%
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Healthcare)1.9%
Analyst forecast (ENZ) (up to 3 years)n/a

Notable Dividend: ENZ's dividend (52.45%) is higher than the bottom 25% of dividend payers in the US market (1.45%).

High Dividend: ENZ's dividend (52.45%) is in the top 25% of dividend payers in the US market (4.5%)

Earnings Payout to Shareholders

Earnings Coverage: ENZ is paying a dividend but the company is unprofitable.

Cash Payout to Shareholders

Cash Flow Coverage: ENZ is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/10/31
Annual Earnings2024/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enzo Biochem, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley BerningCraig-Hallum Capital Group LLC
Reni BenjaminRodman & Renshaw, LLC
Jack WallaceSidoti & Company, LLC